Chordoma Disease Companies
Chordoma is a rare type of cancer that occurs in the bones of the skull base and spine. Companies involved in addressing chordoma may focus on diagnostics, treatments, pharmaceuticals, and supportive care.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Â
Latest Chordoma Disease Companies Update
January 2024:A Phase II clinical trial evaluating the safety and efficacy of ibrutinib (Calquence) in combination with everolimus (Afinitor) for advanced Chordoma is underway at MD Anderson Cancer Center.
December 2023:A study published in the Journal of Clinical Oncology suggests that immunotherapy with pembrolizumab (Keytruda) may offer promising results in patients with advanced Chordoma.
November 2023:Researchers from the University of California San Francisco announce the identification of a new genetic mutation associated with Chordoma, potentially paving the way for targeted therapy development.
October 2023:Blue Sphere Corporation receives orphan drug designation from the FDA for its investigational drug, BLS-804, for the treatment of Chordoma.
September 2023:Sanofi partners with the Chordoma Foundation to support research and development efforts for Chordoma treatment.
August 2023:The Chordoma Foundation launches a new research initiative focused on identifying biomarkers for early diagnosis of Chordoma.
List of Chordoma Disease Key Companies in the Market
- AstraZeneca plc (U.K.)
- Amgen, Inc. (U.S.)
- Actavis plc (U.S.)
- Bristol-Myers Squibb and Company (U.S.)
- Celgene Corporation (U.S.)
- Eli Lilly and Company (U.S.)
- Hoffmann-La Roche AG (Switzerland)
- GlaxoSmithKline plc (UK)
- Novartis International AG (Switzerland)
- Pfizer, Inc. (U.S.)
- Sanofi S.A. (France)
- Debiopharm Group (Switzerland)
- Bayer AG (Germany)
- Johnson & Johnson (U.S.)
- Merck & Co., Inc. (U.S.)
- Optivus Proton Therapy, Inc. (U.S.)
- ProCure Treatment Centers, Inc. (U.S.)
- Varian Medical Systems, Inc.(U.S.)
- Amura Holdings Ltd. (U.S.)
- Catena pharmaceuticals Inc. (U.S.)
- Celldex therapeutics Inc. (U.S.)
- Eckert & Ziegler BEBIG (Germany)
- Infinity Pharmaceuticals (U.S.)
- Medivir AB (Sweden)
- Merrion Pharmaceuticals Plc. (U.S.).
Chordoma Disease Market Highlights:
Chordoma Disease Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
